Christopher E. Mason

Christopher E. Mason's AcademicInfluence.com Rankings

Biology

#15629

World Rank

#19654

Historical Rank

Genetics

#1845

World Rank

#1961

Historical Rank

biology Degrees

Download Badge

Biology

Christopher E. Mason's Degrees

Bachelors Genetics University of California, Berkeley

Why Is Christopher E. Mason Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christopher E. Mason's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A brief definition of regenerative medicine. (2008) (627)
Lancet Commission: Stem cells and regenerative medicine (2017) (159)
Cell therapy industry: billion dollar global business with unlimited potential. (2011) (152)
Peak serum: implications of serum supply for cell therapy manufacturing. (2012) (119)
Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. (2010) (115)
Activation of Pluripotency Genes in Human Fibroblast Cells by a Novel mRNA Based Approach (2010) (114)
Mechanical dynamics of single cells during early apoptosis. (2009) (98)
The potential of optical coherence tomography in the engineering of living tissue. (2004) (90)
Regenerative medicine bioprocessing: building a conceptual framework based on early studies. (2006) (78)
Bioprocess Forces and Their Impact on Cell Behavior: Implications for Bone Regeneration Therapy (2011) (75)
The impact of manual processing on the expansion and directed differentiation of embryonic stem cells (2008) (74)
Regenerative medicine 2.0. (2007) (68)
A decade of cell therapy clinical trials (2000-2010). (2012) (67)
Assessing the value of autologous and allogeneic cells for regenerative medicine. (2009) (64)
International community consensus standard for reporting derivation of human embryonic stem cell lines. (2007) (59)
Hypoxia enhances the generation of retinal progenitor cells from human induced pluripotent and embryonic stem cells. (2012) (56)
Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. (2015) (52)
Regenerative medicine bioprocessing: the need to learn from the experience of other fields. (2006) (51)
Cell therapy medical tourism: time for action. (2010) (50)
Doppler optical coherence tomography for measuring flow in engineered tissue. (2004) (50)
What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic? (2012) (50)
The effect of Young's modulus on the neuronal differentiation of mouse embryonic stem cells. (2015) (47)
Quantities of cells used for regenerative medicine and some implications for clinicians and bioprocessors. (2009) (47)
Corneal epithelial stem cells in health and disease (2006) (45)
Engineering Efficient Retinal Pigment Epithelium Differentiation From Human Pluripotent Stem Cells (2014) (44)
Scale-up of human embryonic stem cell culture using a hollow fibre bioreactor (2012) (44)
Mapping correlated membrane pulsations and fluctuations in human cells (2007) (43)
Regen: the industry responsible for cell-based therapies. (2009) (39)
The strong financial case for regenerative medicine and the regen industry. (2008) (38)
Part 1: Defining unproven cellular therapies. (2016) (36)
Proposal for a universal minimum information convention for the reporting on the derivation of human embryonic stem cell lines. (2006) (33)
The impact of market volatility on the cell therapy industry. (2011) (32)
Induced pluripotent stem cells: an emerging technology platform and the Gartner hype cycle. (2009) (29)
The global cell therapy industry continues to rise during the second and third quarters of 2012. (2012) (28)
Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discovery (2009) (27)
Viscoelastic, physical, and bio-degradable properties of dermal scaffolds and related cell behaviour (2016) (25)
Reproducible culture and differentiation of mouse embryonic stem cells using an automated microwell platform☆ (2013) (23)
Cell therapy worldwide: an incipient revolution. (2015) (23)
Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series. (2016) (23)
Cell therapy companies make strong progress from October 2012 to March 2013 amid mixed stock market sentiment. (2013) (19)
Defeating stem cell tourism. Foreword. (2010) (19)
Effect of Sub-Atmospheric Oxygen on the Culture of Rabbit Limbal Epithelial Cells (2011) (18)
Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products. (2015) (18)
The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine. (2010) (18)
The full spectrum of physiological oxygen tensions and step‐changes in oxygen tension affects the neural differentiation of mouse embryonic stem cells (2011) (16)
The 3Rs of Cell Therapy (2016) (16)
Precisely delivered nanomechanical forces induce blebbing in undifferentiated mouse embryonic stem cells (2011) (16)
Effect of capillary shear stress on recovery and osteogenic differentiation of muscle‐derived precursor cell populations (2011) (14)
Stem cell nations working together for a stem cell world. (2010) (14)
New era dawns for US stem cell research. (2009) (14)
Human embryonic stem cell therapy in the post-Geron era. (2012) (13)
Lessons for the nascent regenerative medicine industry from the biotech sector. (2007) (13)
The need for a regen industry voice. (2008) (13)
Promising growth and investment in the cell therapy industry during the first quarter of 2012. (2012) (13)
Regenerative medicine. The industry comes of age. (2007) (13)
Automated tissue engineering: a major paradigm shift in health care. (2003) (12)
Tissue engineering skin: a paradigm shift in wound care. (2005) (12)
Translational regenerative medicine research: essential to discovery and outcome. (2007) (12)
The time has come to engineer tissues and not just tissue engineer. (2006) (11)
Streamlining Cell Therapy Manufacture (2012) (11)
The crucial linkage required between regenerative medicine bioprocessors and clinicians. (2008) (10)
Design of a Novel Two-Component Hybrid Dermal Scaffold for the Treatment of Pressure Sores. (2017) (10)
Hypoxic culture of human pluripotent stem cell lines is permissible using mouse embryonic fibroblasts. (2012) (10)
Donor Variability in Growth Kinetics of Healthy hMSCs Using Manual Processing: Considerations for Manufacture of Cell Therapies. (2018) (10)
ISSCR 2009 Industry Panel Session: promoting translation and commercialization. (2009) (9)
Method for estimating protein binding capacity of polymeric systems (2015) (8)
Directed Differentiation of Embryonic Stem Cells Using a Bead-Based Combinatorial Screening Method (2014) (7)
Cells: from Robert Hooke to cell therapy—a 350 year journey (2015) (6)
Evolving Industry Partnerships and Investments in Cell and Gene Therapies. (2018) (6)
Cell therapy commercialisation (2012) (6)
Pharmaceutical industry: Investors unfazed by drug-patent expiry (2012) (5)
Evolving Industry Partnerships and Investments in Cell and Gene Therapies. (2018) (5)
'The Little Purple Book': BSI glossary of regenerative medicine. Foreword. (2009) (5)
Mapping the human embryome: 1 to 10e13 and all the cells in between. (2007) (5)
Stem cells are big news, but are they big business? (2005) (5)
Bioprocessing strategies to enhance the challenging isolation of neuro-regenerative cells from olfactory mucosa (2018) (5)
Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation. (2012) (5)
Oxygen-controlled automated neural differentiation of mouse embryonic stem cells. (2013) (5)
'The Little Purple Book', 2nd edition: Cell therapy and regenerative medicine glossary. (2012) (5)
A novel filtration system for point of care washing of cellular therapy products (2017) (5)
Regenerative medicine: revolution in the making. (2005) (4)
A novel filtration device for point of care preparation of cellular therapies (2015) (4)
Influence of Initial Seeding Density on Gene Expression during Neuronal Priming (2015) (4)
Cell & Gene Therapy, and Regenerative Medicine – Different Definitions (2016) (4)
Cell Therapy Regulatory Toolkit: an online regulatory resource. (2015) (4)
Altered hMSC functional characteristics in short-term culture and when placed in low oxygen environments: implications for cell retention at physiologic sites. (2014) (3)
Generation of c-MycERTAM-transduced human late-adherent olfactory mucosa cells for potential regenerative applications (2019) (3)
Albumin removal from human fibrinogen preparations for manufacturing human fibrin-based biomaterials (2015) (2)
Stem cell prospects (2008) (2)
The 3Rs of Cell Therapy. (2016) (2)
The Korean stem cell fiasco: shifting the focus. (2006) (2)
Revolutionary therapies for diabetes--catalysts for change. Foreword. (2009) (2)
Precisely delivered nano-mechanical forces induce blebbing in undifferentiated mouse embryonic stem cells (2011) (1)
Scale-up of human embryonic stem cell culture using a hollow fibre bioreactor (2012) (1)
Bioaesthetics and regenerative medicine. (2009) (1)
Other approaches to fighting cardiovascular disease: stem cells and engineered tissue. (2006) (1)
A new cell therapy sector arising from the convergence of cell and gene therapy (2013) (1)
Streamlining Cell Therapy ManufactureClinical to Commercial Scale (2012) (1)
A changing time: the International Society for Cellular Therapy embraces its industry members. (2010) (1)
Methods employing cells derived from adult bone marrow (2003) (1)
A platform for predictive bioprocessing of autologous cells for therapy based on automated microwell cultures (2008) (1)
The effect of microwell size and inoculation density on the automated processing of stem cells (2006) (0)
Introducing the special focus issue: cellular reprogramming and iPS cells. (2010) (0)
Time to move away from the ‘your process is your product’ paradigm? (2016) (0)
Atomic force microscopy and con-focal imaging of living cells and tissues (2006) (0)
A US Cell Therapy Regulatory Toolkit (2015) (0)
High-resolution cellular and molecular follow up of lysosomal disease patients treated with hematopoietic stem cell lentiviral gene therapy (2022) (0)
Human Embryonic Stem Cells: Derivation and Culture (2008) (0)
A dynamic oscillation in cell membrane stiffness is an early indicator of apoptosis in human cells (2006) (0)
Study of a novel tube forming method for preparing engineered blood vessels (2012) (0)
Cost of stem cell-based tissue-engineered airway transplants in the UK: Case series (2015) (0)
High-throughput characterization of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing. (2022) (0)
The response of embryonic stem cells to extra-cellular forces (2008) (0)
Genetically engineered microglia-like cells have therapeutic potential for neurodegenerative disease (2021) (0)
Long-term hematopoietic stem cell lentiviral gene therapy rescues neuromuscular manifestations in preclinical study of Pompe disease mice (2022) (0)
452. RegenVOX - Translational Exploitation Strategy for Stem Cell-Based Tissue-Engineered Laryngeal Implants Undergoing Phase I/II Clinical Trial (2016) (0)
Bioprocessing strategies to enhance the challenging isolation of neuro-regenerative cells from olfactory mucosa (2018) (0)
Stem cells: the blue print for the future. (2006) (0)
Spotlight on : Translation and applications of gene editing (2015) (0)
REGENVOX: A phase I/II clinical trial of stem cell-based tissue-engineered laryngeal implants. (2015) (0)
Kanazawa Workshop on Atomic Force Microscopy (2007) (0)
Intermediate Oxygen Tensions Promote Maintenance and Expansion of the Limbal Epithelial Stem Cell Phenotype (2009) (0)
Flow Cytometry Assay to Monitor Effectiveness of Gene Therapy Correction in Peripheral Blood Mononuclear Cells of Gaucher Disease Type I Patients (2018) (0)
The automation of stem cell bioprocessing - prelimiary studies comparing human mesenchymal stem cell and mouse embryinic stem cell expansion (2006) (0)
Peak Supply: Implications of Serum and Consumable Availability for Clinicians, Researchers, and Commercial Translation (2012) (0)
Cell Therapy Industry Market Characteristics: Implications for Clinicians, Investors, Patients and Translational Researchers (2012) (0)
A Comprehensive High Resolution Scrna-Seq Analytical Platform for Characterizing Human Hematopoietic Stem/Progenitor Cells States in Ex Vivo Drug Products (2020) (0)
Controlling the embryonic stem cell microenvironment in culture: inherent variations associated with manual handling and opportunities for automation (2007) (0)
The Effect of Human Embryonic Stem Cell Seeding Density on the Timing and Yield of Differentiation into Retinal Pigment Epithelium (2011) (0)
Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan? (2020) (0)
The Integration of Manufacturing and Delivery into Healthcare Systems (2016) (0)
Preliminary studies in the automation of stem cell bioprocessing (2006) (0)
Advanced cell therapies – progress towards the clinic (2016) (0)
Reprogramming cell fate using mRNA of defined factors (2008) (0)
Automated approaches to stem cell culture for drug discovery and cell therapy (2008) (0)
High throughput monitoring of safety, potency and stability of gene therapy cell products in lysosomal disease patients (2022) (0)
IMPROVING YIELD AND EXPANSION OF PRIMARY OLFACTORY ENSHEATHING CELLS TO GENERATE STABLE CELL LINES FOR SPINAL CORD INJURY (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christopher E. Mason?

Christopher E. Mason is affiliated with the following schools:

University College London